Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remicade RA Therapy Meets Medicare Criteria For Infused Drug - Centocor

Executive Summary

Centocor has been communicating with the Health Care Financing Administration regarding Medicare coverage for the newly approved rheumatoid arthritis indication for Remicade.

You may also be interested in...



Hatch Bill Would Restrict HCFA Payment System; Enbrel Coverage Sought

Health Care Financing Administration procedures for bringing already-covered drugs under the outpatient prospective payment system would be tightly controlled in legislation introduced Sept. 23 by Sen. Hatch (R-Utah).

Immunex Enbrel

Supplemental BLA submitted July 15 for slowing structural damage and improving the signs and symptoms of early, active rheumatoid arthritis. FDA approved etanercept in November 1998 to treat moderately to severely active RA in patients with no successful drug alternatives and extended the indication to children in May

Immunex Preparing Enbrel Infection Risk Study And BLA For RA Progression

Immunex has agreed to perform large, prospectively defined studies to assess the risk of serious infection related to use of its rheumatoid arthritis therapy Enbrel (etanercept) following reports of sepsis and death with the product.

Related Content

UsernamePublicRestriction

Register

PS035181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel